Pay in 4 interest-free payments of $5.39 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
Our team evaluates every patient individually to ensure safe, appropriate, and effective care.
The conversation around obesity is shifting toward one of a chronic disease rather than a lifestyle choice
Patients who have been on Wegovy or Zepbound through the program would face three options: Pay out of pocket at retail prices (currently $1,000-$1,300 per month) Discontinue the medication , which research suggests leads to significant weight regain Transition to an alternative covered treatment , such as bariatric surgery or other covered medications The STEP 1 extension study showed that patients who discontinued semaglutide regained approximately two-thirds of their lost weight within one year
GHK-Cu Overview: National Center for Biotechnology Information (2026)
Elevated Healthcare Standards : Our membership model transcends traditional healthcare approaches, raising the bar for quality and personalized care
Coverage for Wegovy and Zepbound CMS states that, at this time, the GLP-1 drugs which will be eligible for coverage under the Bridge Program will be Wegovy (injection and tablets) and Zepbound
